Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer

Table 3

Relationship between expression of CMTM6 and PD-L1 protein and clinicopathological features of TNBC.

Clinicopathological features		Protein expression
		CMTM6				PD-L1
		—	+	PR (%)	value	—	+	PR (%)	value
Age
≤50	36	14	22	61.1	0.147	24	12	33.3	0.181
>50	53	25	28	52.8		39	14	26.4
Size
<3	50	25	25	50.0	0.043	38	12	24.0	0.022
≥3	39	14	25	64.1		25	14	35.9
Lymph node metastasis
-	54	27	28	51.9	0.028	47	8	14.8	<0.001
+	34	12	22	64.7		16	18	52.9
Distant metastasis
-	81	36	45	55.6	0.298	60	21	25.9	0.273
+	8	3	5	62.5		3	5	62.5
TNM stage
I	73	34	39	53.4	0.003	57	16	21.9	0.039
II-III	16	5	11	68.8		6	10	62.5
Histological grade
I	38	15	23	60.5	0.187	31	7	18.4	<0.001
II-III	51	24	27	52.9		32	19	37.3
Vascular infiltration
-	52	25	27	51.9	0.091	41	11	21.2	0.001
+	37	14	23	62.2		22	15	40.5
Nerve invasion
-	75	34	41	54.7	0.076	53	22	29.3	0.909
+	14	5	9	64.3		10	4	28.6
TP53
-	23	11	12	52.2	0.531	17	6	26.1	0.429
+	66	28	38	57.6		46	20	30.3
Ki67
-	10	8	2	20.0	<0.001	10	0	0.0	<0.001
+	79	31	48	60.8		53	26	32.9

PR: positive rate.